Immunotherapy Tops CRISPR Agenda – OncLive
OncLive |
Immunotherapy Tops CRISPR Agenda
OncLive “We have been using genetic manipulation to redirect T cells for about 15 years now, but it has always been a slow and expensive process,” said Marcela V. Maus, MD, PhD, director of cellular immunotherapy at Massachusetts General Hospital Cancer Center … |
